Skip to content

Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries

A Feasibility Study to Evaluate the Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusion in Coronary Arteries

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00618020
Enrollment
10
Registered
2008-02-18
Start date
2007-08-31
Completion date
2008-02-29
Last updated
2008-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Occlusion

Keywords

CTO, Chronic Total Occlusion, Revascularization

Brief summary

The CiTop™ guidewire Coronary study is a feasibility open label study, to evaluate the safety and efficacy of the CiTop™ Guidewire for crossing chronic total occlusion in Coronary arteries.

Interventions

CiTop(tm)6 Guidewire

Sponsors

Ovalum
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Informed consent obtained prior to any trial activities. 2. Patients, male or female between 21 and 80 years of age, with no significant co-morbidities (see

Exclusion criteria

). 3. Patient has an angiographic documented Chronic Total Occlusion showing distal TIMI flow 0 to 1.

Design outcomes

Primary

MeasureTime frame
Angiographic documentation of placement of CiTop™ distal to occlusion with no device related major complications.during procedure, 1day, 1week and 30 days post procedure

Secondary

MeasureTime frame
Wire crossing durationduring procedure
Fluoroscopy timeduring procedure
Successful stentingDuring procedure, Day1, Day7 and Day30 post procedure
Maneuverability of the CiTop™ up to the occlusionduring procedure
No mechanical damage to the device duringduring procedure
Amount of contrastduring procedure

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026